{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:45:31Z","timestamp":1777481131170,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI138495"],"award-info":[{"award-number":["R01AI138495"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI138494"],"award-info":[{"award-number":["R21AI138494"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.cellimm.2021.104457","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T20:09:11Z","timestamp":1637698151000},"page":"104457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production"],"prefix":"10.1016","volume":"371","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-4335","authenticated-orcid":false,"given":"Marcela T.","family":"Taruselli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Motunrayo","family":"Kolawole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina Abdul","family":"Qayum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara T.","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather L.","family":"Caslin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-3028","authenticated-orcid":false,"given":"Daniel","family":"Abebayehu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4828","authenticated-orcid":false,"given":"Sydney A.","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan M.","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2663-9593","authenticated-orcid":false,"given":"Kaitlyn G.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason R.","family":"Burchett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Spence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-7902","authenticated-orcid":false,"given":"Neha","family":"Pondicherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian O.","family":"Barnstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cellimm.2021.104457_b0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ajpath.2015.07.025","article-title":"The mast cell-IgE paradox: from homeostasis to anaphylaxis","volume":"186","author":"Galli","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.cellimm.2021.104457_b0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/10799893.2019.1690515","article-title":"IL-33 mediated amplification of allergic response in human mast cells","volume":"39","author":"Parveen","year":"2019","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.cellimm.2021.104457_b0020","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1189\/jlb.0407200","article-title":"IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals","volume":"82","author":"Ho","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"47","key":"10.1016\/j.cellimm.2021.104457_b0025","doi-asserted-by":"crossref","first-page":"18660","DOI":"10.1073\/pnas.0705939104","article-title":"IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells","volume":"104","author":"Ali","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.cellimm.2021.104457_b0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.it.2017.10.005","article-title":"Cells as drivers of disease and therapeutic targets","volume":"39","author":"Siebenhaar","year":"2018","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2021.104457_b0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2019.1596800","article-title":"Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?","volume":"15","author":"Theoharides","year":"2019","journal-title":"Expert, Rev, Clin, Immunol,"},{"issue":"11","key":"10.1016\/j.cellimm.2021.104457_b0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"22","author":"Salami","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.cellimm.2021.104457_b0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-009-0150-y","article-title":"Update on statin-mediated anti-inflammatory activities in atherosclerosis","volume":"31","author":"Montecucco","year":"2009","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0055","doi-asserted-by":"crossref","first-page":"e12352","DOI":"10.14814\/phy2.12352","article-title":"Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins","volume":"3","author":"Zeki","year":"2015","journal-title":"Physiol. Rep."},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0060","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1183\/09031936.00050612","article-title":"Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic-polycytidylic acid-induced pneumonia","volume":"41","author":"Lee","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/1874467209666160112125911","article-title":"Clinical Studies of statins in asthma and COPD","volume":"10","author":"Thomson","year":"2017","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cellimm.2021.104457_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/835204","article-title":"Statins in asthma: potential beneficial effects and limitations","volume":"2015","author":"Bhattacharjee","year":"2015","journal-title":"Pulm. Med."},{"issue":"9","key":"10.1016\/j.cellimm.2021.104457_b0075","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1038\/emm.2014.55","article-title":"Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?","volume":"46","author":"Liu","year":"2014","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.cellimm.2021.104457_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003314","article-title":"Statin use and asthma control in patients with severe asthma","volume":"3","author":"Zeki","year":"2013","journal-title":"BMJ Open"},{"issue":"19","key":"10.1016\/j.cellimm.2021.104457_b0085","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2146\/ajhp120680","article-title":"Statins in the treatment of asthma","volume":"70","author":"Walker","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"9","key":"10.1016\/j.cellimm.2021.104457_b0090","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/02770903.2012.721433","article-title":"A systematic review of statin efficacy in asthma","volume":"49","author":"Silva","year":"2012","journal-title":"J. Asthma"},{"key":"10.1016\/j.cellimm.2021.104457_b0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2362.2010.02434.x","article-title":"Statin use in patients with asthma: a nationwide population-based study","volume":"41","author":"Huang","year":"2011","journal-title":"Eur. J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.cellimm.2021.104457_b0100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/thx.2010.138990","article-title":"Simvastatin in the treatment of asthma: lack of steroid-sparing effect","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.cellimm.2021.104457_b0105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jaci.2006.10.014","article-title":"Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma","volume":"119","author":"Menzies","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2-3","key":"10.1016\/j.cellimm.2021.104457_b0110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ejphar.2008.11.040","article-title":"Fluvastatin inhibits mast cell degranulation without changing the cytoplasmic Ca2+ level","volume":"602","author":"Fujimoto","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.cellimm.2021.104457_b0115","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.4049\/jimmunol.1501932","article-title":"Fluvastatin suppresses mast cell and basophil IgE responses: genotype-dependent effects","volume":"196","author":"Kolawole","year":"2016","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1124\/jpet.119.264234","article-title":"Fluvastatin induces apoptosis in primary and transformed mast cells","volume":"374","author":"Paez","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.cellimm.2021.104457_b0125","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ni.3487","article-title":"Control of the innate immune response by the mevalonate pathway","volume":"17","author":"Akula","year":"2016","journal-title":"Nat. Immunol."},{"issue":"23","key":"10.1016\/j.cellimm.2021.104457_b0130","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.1158\/0008-5472.CAN-10-1968","article-title":"IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells","volume":"70","author":"Gruenbacher","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2021.104457_b0135","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fimmu.2020.01150","article-title":"Management of mevalonate kinase deficiency: a pediatric perspective","volume":"11","author":"Jeyaratnam","year":"2020","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.cellimm.2021.104457_b0140","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2008-03-144667","article-title":"HMG-CoA reductase inhibition induces IL-1beta release through Rac1\/PI3K\/PKB-dependent caspase-1 activation","volume":"112","author":"Kuijk","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cellimm.2021.104457_b0145","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.molimm.2007.12.008","article-title":"Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1","volume":"45","author":"Kuijk","year":"2008","journal-title":"Mol. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbagen.2018.01.020","article-title":"Interleukin-6 potentiates FcepsilonRI-induced PGD(2) biosynthesis and induces VEGF from human in situ-matured skin mast cells","volume":"1862","author":"McHale","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.cellimm.2021.104457_b0155","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3389\/fimmu.2019.01445","article-title":"Human skin-derived mast cells spontaneously secrete several angiogenesis-related factors","volume":"10","author":"McHale","year":"2019","journal-title":"Front Immunol."},{"issue":"1-2","key":"10.1016\/j.cellimm.2021.104457_b0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2017.11.025","article-title":"Metabolic Induction of Trained Immunity through the Mevalonate Pathway","volume":"172","author":"Bekkering","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cellimm.2021.104457_b0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5213\/inj.2015.19.3.142","article-title":"Interleukin-33 and mast cells bridge innate and adaptive immunity: from the allergologist's perspective","volume":"19","author":"Jang","year":"2015","journal-title":"Int. Neurourol. J."},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12636","article-title":"Is it time for a new classification of mast cells? What do we know about mast cell heterogeneity?","volume":"282","author":"Frossi","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2021.104457_b0175","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V97.7.2045","article-title":"Human skin-derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes","volume":"97","author":"Kambe","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2021.104457_b0180","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-10-247411","article-title":"The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells","volume":"115","author":"Drube","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2021.104457_b0185","doi-asserted-by":"crossref","first-page":"40261","DOI":"10.1074\/jbc.M506063200","article-title":"Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit","volume":"280","author":"Iwaki","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1084\/jem.174.1.103","volume":"174","author":"Gordon","year":"1991","journal-title":"J Exp Med."},{"key":"10.1016\/j.cellimm.2021.104457_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/617170","article-title":"Cytokine response of cultured skeletal muscle cells stimulated with proinflammatory factors depends on differentiation stage","volume":"2013","author":"Podbregar","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.cellimm.2021.104457_b0200","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1600651","article-title":"Lactic acid suppresses IL-33-mediated mast cell inflammatory responses via hypoxia-inducible Factor-1alpha-dependent miR-155 suppression","volume":"197","author":"Abebayehu","year":"2016","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2021.104457_b0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jir.2012.0066","article-title":"Murine mast cells secrete and respond to interleukin-33","volume":"34","author":"Tung","year":"2014","journal-title":"J. Interferon. Cytokine Res."},{"key":"10.1016\/j.cellimm.2021.104457_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54878-5","article-title":"Resveratrol inhibits IL-33-mediated mast cell activation by targeting the MK2\/3-PI3K\/Akt axis","volume":"9","author":"Nakajima","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellimm.2021.104457_b0215","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4049\/jimmunol.1601983","article-title":"TGF-beta1 suppresses IL-33-induced mast cell function","volume":"199","author":"Ndaw","year":"2017","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000503976","article-title":"Interleukin-33 promotes Th2\/Th17 response in eosinophilic and non-eosinophilic nasal polyps","volume":"82","author":"Luo","year":"2020","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"10.1016\/j.cellimm.2021.104457_b0225","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/OTT.S155905","article-title":"Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells","volume":"11","author":"Yang","year":"2018","journal-title":"Onco. Targets Ther."},{"issue":"1-2","key":"10.1016\/j.cellimm.2021.104457_b0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12026-012-8283-9","article-title":"IL-33\/ST2 axis in inflammation and immunopathology","volume":"52","author":"Milovanovic","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cellimm.2021.104457_b0235","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2012-05-434209","article-title":"Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent","volume":"121","author":"Enoksson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2021.104457_b0240","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-11-16","article-title":"Effects of short-term treatment with atorvastatin in smokers with asthma\u2013a randomized controlled trial","volume":"11","author":"Braganza","year":"2011","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0245","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1055-9965.EPI-15-0052","article-title":"Statin use and survival from lung cancer: a population-based cohort study","volume":"24","author":"Cardwell","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"10","key":"10.1016\/j.cellimm.2021.104457_b0250","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2006-09-047076","article-title":"Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation","volume":"109","author":"Dai","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cellimm.2021.104457_b0255","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2004.02.016","article-title":"Statin-induced immunomodulatory effects on human T cells in vivo","volume":"175","author":"Fehr","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cellimm.2021.104457_b0260","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-018-0140-0","article-title":"Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia","volume":"6","author":"Henslee","year":"2018","journal-title":"Biomark Res."},{"issue":"12","key":"10.1016\/j.cellimm.2021.104457_b0265","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/thx.2008.100198","article-title":"Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma","volume":"63","author":"Hothersall","year":"2008","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0270","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/s10165-007-0589-4","article-title":"Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1\/Th2 and CD4\/CD8 ratios","volume":"17","author":"Kanda","year":"2007","journal-title":"Mod. Rheumatol."},{"issue":"8","key":"10.1016\/j.cellimm.2021.104457_b0275","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cardfail.2006.05.003","article-title":"Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials","volume":"12","author":"Khush","year":"2006","journal-title":"J. Card. Fail."},{"issue":"4","key":"10.1016\/j.cellimm.2021.104457_b0280","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaci.2010.08.005","article-title":"Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase","volume":"126","author":"Maneechotesuwan","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cellimm.2021.104457_b0285","first-page":"236","article-title":"Efficacy of atorvastatin and antihistamines in comparison with antihistamines plus placebo in the treatment of chronic idiopathic urticaria: a controlled clinical trial","volume":"11","author":"Pezeshkpoor","year":"2012","journal-title":"Iran J. Allergy Asthma Immunol."},{"issue":"9","key":"10.1016\/j.cellimm.2021.104457_b0290","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1158\/0008-5472.CAN-06-3686","article-title":"Suppressive effects of statins on acute promyelocytic leukemia cells","volume":"67","author":"Sassano","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2021.104457_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.01.001","article-title":"Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma","volume":"31","author":"Thomson","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cellimm.2021.104457_b0300","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biocel.2012.11.001","article-title":"Statins, autophagy and cancer metastasis","volume":"45","author":"Zhang","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.cellimm.2021.104457_b0305","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1398-9995.2006.00997.x","article-title":"Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells","volume":"61","author":"Krauth","year":"2006","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0310","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1084\/jem.192.5.729","article-title":"Akt-dependent cytokine production in mast cells","volume":"192","author":"Kitaura","year":"2000","journal-title":"J. Exp. Med."},{"issue":"35","key":"10.1016\/j.cellimm.2021.104457_b9001","doi-asserted-by":"crossref","first-page":"32124","DOI":"10.1074\/jbc.M203298200","article-title":"The phosphatidylinositol 3-Kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells","volume":"277","author":"Guha","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cellimm.2021.104457_b9002","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.4049\/jimmunol.180.6.4218","article-title":"Genetic analysis of the role of the PI3K-Akt Pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes\/macrophages","volume":"180","author":"Luyendyk","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2021.104457_b0315","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cells9051110","article-title":"Targeting GSK3 and associated signaling pathways involved in cancer","volume":"9","author":"Duda","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.cellimm.2021.104457_b0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.cellimm.2021.104457_b0325","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.4049\/jimmunol.1600658","article-title":"MK2\/3 Are pivotal for IL-33-induced and mast cell-dependent leukocyte recruitment and the resulting skin inflammation","volume":"197","author":"Drube","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2021.104457_b0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000236928","article-title":"Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor","volume":"107","author":"Galli","year":"1995","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.cellimm.2021.104457_b0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.amjcard.2020.09.050","article-title":"Statin treatment of COVID-19","volume":"136","author":"Fedson","year":"2020","journal-title":"Am. J. Cardiol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874921001763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874921001763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:42Z","timestamp":1777385502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874921001763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":69,"alternative-id":["S0008874921001763"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2021.104457","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2021.104457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104457"}}